Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1953 2
1954 1
1955 1
1956 2
1958 1
1959 7
1961 1
1962 1
1963 1
1964 2
1965 3
1966 4
1967 18
1968 6
1969 21
1970 12
1971 15
1972 22
1973 15
1974 25
1975 30
1976 19
1977 18
1978 31
1979 35
1980 33
1981 29
1982 42
1983 47
1984 60
1985 48
1986 54
1987 67
1988 56
1989 69
1990 67
1991 101
1992 86
1993 75
1994 105
1995 95
1996 95
1997 94
1998 109
1999 102
2000 115
2001 129
2002 137
2003 167
2004 156
2005 183
2006 182
2007 207
2008 200
2009 207
2010 263
2011 276
2012 282
2013 269
2014 323
2015 357
2016 364
2017 377
2018 389
2019 440
2020 526
2021 556
2022 479
2023 455
2024 211

Text availability

Article attribute

Article type

Publication date

Search Results

7,955 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Interstitial lung disease 2"
Page 1
Interstitial Lung Disease: A Review.
Maher TM. Maher TM. JAMA. 2024 May 21;331(19):1655-1665. doi: 10.1001/jama.2024.3669. JAMA. 2024. PMID: 38648021 Review.
IMPORTANCE: Interstitial lung disease (ILD) consists of a group of pulmonary disorders characterized by inflammation and/or fibrosis of the lung parenchyma associated with progressive dyspnea that frequently results in end-stage respiratory failure. .. …
IMPORTANCE: Interstitial lung disease (ILD) consists of a group of pulmonary disorders characterized by inflammation an …
Smoking-Related Interstitial Lung Diseases.
Alarcon-Calderon A, Vassallo R, Yi ES, Ryu JH. Alarcon-Calderon A, et al. Immunol Allergy Clin North Am. 2023 May;43(2):273-287. doi: 10.1016/j.iac.2023.01.007. Epub 2023 Mar 1. Immunol Allergy Clin North Am. 2023. PMID: 37055089 Review.
Smoking-related interstitial lung diseases (ILDs) are a group of heterogeneous, diffuse pulmonary parenchymal disease processes associated with tobacco exposure. ...We also discuss the interstitial lung abnormalities incidentally detected …
Smoking-related interstitial lung diseases (ILDs) are a group of heterogeneous, diffuse pulmonary parenchymal diseas …
Expert consensus on the management of systemic sclerosis-associated interstitial lung disease.
Rahaghi FF, Hsu VM, Kaner RJ, Mayes MD, Rosas IO, Saggar R, Steen VD, Strek ME, Bernstein EJ, Bhatt N, Castelino FV, Chung L, Domsic RT, Flaherty KR, Gupta N, Kahaleh B, Martinez FJ, Morrow LE, Moua T, Patel N, Shlobin OA, Southern BD, Volkmann ER, Khanna D. Rahaghi FF, et al. Respir Res. 2023 Jan 9;24(1):6. doi: 10.1186/s12931-022-02292-3. Respir Res. 2023. PMID: 36624431 Free PMC article.
BACKGROUND: Systemic sclerosis (SSc) is a rare, complex, connective tissue disorder. Interstitial lung disease (ILD) is common in SSc, occurring in 35-52% of patients and accounting for 20-40% of mortality. ...Concomitant use of nintedanib with MMF/cyclophosp …
BACKGROUND: Systemic sclerosis (SSc) is a rare, complex, connective tissue disorder. Interstitial lung disease (ILD) is …
Interstitial Pneumonia with Autoimmune Features.
Graney BA, Fischer A. Graney BA, et al. Ann Am Thorac Soc. 2019 May;16(5):525-533. doi: 10.1513/AnnalsATS.201808-565CME. Ann Am Thorac Soc. 2019. PMID: 30695649 Free PMC article. Review.
Interstitial pneumonia with autoimmune features (IPAF) is a research classification proposed by the European Respiratory Society/American Thoracic Society Task Force on Undifferentiated Forms of Connective Tissue Disease-associated Interstitial Lung …
Interstitial pneumonia with autoimmune features (IPAF) is a research classification proposed by the European Respiratory Society/Amer …
Treatment for systemic sclerosis-associated interstitial lung disease.
Roofeh D, Lescoat A, Khanna D. Roofeh D, et al. Curr Opin Rheumatol. 2021 May 1;33(3):240-248. doi: 10.1097/BOR.0000000000000795. Curr Opin Rheumatol. 2021. PMID: 33741803 Free PMC article. Review.
PURPOSE OF REVIEW: This review provides an overview of the current treatments for systemic sclerosis-interstitial lung disease (SSc-ILD) and proposes a conceptual framework for disease management with case scenarios. ...The optimal use of each option v …
PURPOSE OF REVIEW: This review provides an overview of the current treatments for systemic sclerosis-interstitial lung dise …
Multidisciplinary clinical guidance on trastuzumab deruxtecan (T-DXd)-related interstitial lung disease/pneumonitis-Focus on proactive monitoring, diagnosis, and management.
Swain SM, Nishino M, Lancaster LH, Li BT, Nicholson AG, Bartholmai BJ, Naidoo J, Schumacher-Wulf E, Shitara K, Tsurutani J, Conte P, Kato T, Andre F, Powell CA. Swain SM, et al. Cancer Treat Rev. 2022 May;106:102378. doi: 10.1016/j.ctrv.2022.102378. Epub 2022 Mar 12. Cancer Treat Rev. 2022. PMID: 35430509 Free article. Review.
Trastuzumab deruxtecan (T-DXd; DS-8201) is an antibody-drug conjugate targeting human epidermal growth factor receptor 2. Interstitial lung disease (ILD)/pneumonitis is an adverse event associated with T-DXd; in most cases, it is low grade (grade 2 …
Trastuzumab deruxtecan (T-DXd; DS-8201) is an antibody-drug conjugate targeting human epidermal growth factor receptor 2. Intersti …
Cyclophosphamide for connective tissue disease-associated interstitial lung disease.
Barnes H, Holland AE, Westall GP, Goh NS, Glaspole IN. Barnes H, et al. Cochrane Database Syst Rev. 2018 Jan 3;1(1):CD010908. doi: 10.1002/14651858.CD010908.pub2. Cochrane Database Syst Rev. 2018. PMID: 29297205 Free PMC article. Review.
BACKGROUND: Approximately one-third of individuals with interstitial lung disease (ILD) have associated connective tissue disease (CTD). ...When appropriate, we performed meta-analyses and subgroup analyses by severity of lung function, connecti …
BACKGROUND: Approximately one-third of individuals with interstitial lung disease (ILD) have associated connective tiss …
Treatment Outcomes for Rheumatoid Arthritis-Associated Interstitial Lung Disease: A Real-World, Multisite Study of the Impact of Immunosuppression on Pulmonary Function Trajectory.
Matson SM, Baqir M, Moua T, Marll M, Kent J, Iannazzo NS, Boente RD, Donatelli JM, Dai J, Diaz FJ, Demoruelle MK, Hamblin MB, Mathai SK, Ryu JH, Pope K, Walker CM, Lee JS. Matson SM, et al. Chest. 2023 Apr;163(4):861-869. doi: 10.1016/j.chest.2022.11.035. Epub 2022 Dec 5. Chest. 2023. PMID: 36470416 Free PMC article. Clinical Trial.
BACKGROUND: Rheumatoid arthritis (RA)-associated interstitial lung disease (ILD) is common in patients with RA and leads to significant morbidity and mortality. No randomized, placebo-controlled data are available that support the role of immunosuppres …
BACKGROUND: Rheumatoid arthritis (RA)-associated interstitial lung disease (ILD) is common in patients with RA and lead …
Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial.
Tashkin DP, Roth MD, Clements PJ, Furst DE, Khanna D, Kleerup EC, Goldin J, Arriola E, Volkmann ER, Kafaja S, Silver R, Steen V, Strange C, Wise R, Wigley F, Mayes M, Riley DJ, Hussain S, Assassi S, Hsu VM, Patel B, Phillips K, Martinez F, Golden J, Connolly MK, Varga J, Dematte J, Hinchcliff ME, Fischer A, Swigris J, Meehan R, Theodore A, Simms R, Volkov S, Schraufnagel DE, Scholand MB, Frech T, Molitor JA, Highland K, Read CA, Fritzler MJ, Kim GHJ, Tseng CH, Elashoff RM; Sclerodema Lung Study II Investigators. Tashkin DP, et al. Lancet Respir Med. 2016 Sep;4(9):708-719. doi: 10.1016/S2213-2600(16)30152-7. Epub 2016 Jul 25. Lancet Respir Med. 2016. PMID: 27469583 Free PMC article. Clinical Trial.
METHODS: This randomised, double-blind, parallel group trial enrolled patients from 14 US medical centres with scleroderma-related interstitial lung disease meeting defined dyspnoea, pulmonary function, and high-resolution CT (HRCT) criteria. .. …
METHODS: This randomised, double-blind, parallel group trial enrolled patients from 14 US medical centres with scleroderma-rel …
Systemic Sclerosis-Associated Interstitial Lung Disease: How to Incorporate Two Food and Drug Administration-Approved Therapies in Clinical Practice.
Khanna D, Lescoat A, Roofeh D, Bernstein EJ, Kazerooni EA, Roth MD, Martinez F, Flaherty KR, Denton CP. Khanna D, et al. Arthritis Rheumatol. 2022 Jan;74(1):13-27. doi: 10.1002/art.41933. Epub 2021 Nov 10. Arthritis Rheumatol. 2022. PMID: 34313399 Free PMC article. Review.
Systemic sclerosis (SSc; scleroderma) has the highest individual mortality of all rheumatic diseases, and interstitial lung disease (ILD) is among the leading causes of SSc-related death. ...The objectives of this review are 2-fold: 1) review th …
Systemic sclerosis (SSc; scleroderma) has the highest individual mortality of all rheumatic diseases, and interstitial lung …
7,955 results